Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
KNSA Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Positive2-24
The company demonstrated strong financial performance with significant revenue and net income growth, improved guidance, and robust cash generation. ARCALYST's market penetration shows potential for further growth, and KPL-387 offers promising expansion opportunities. Despite competitive pressures and vague management responses on certain aspects, the overall sentiment remains positive due to raised guidance, strong product adoption, and strategic market positioning. Given the market cap, the expected stock price movement is positive (2% to 8%).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call summary and Q&A indicate strong financial performance, positive feedback from patients and physicians, and increased prescriber numbers for ARCALYST. The raised sales guidance for 2025 and strategic marketing efforts further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, with a focus on growth and market penetration. Given the company's market cap, this is likely to result in a stock price increase of 2% to 8% over the next two weeks.
Kiniksa Pharmaceuticals International, Plc (KNSA) Presents At Citi's Biopharma Back To School Conference Transcript
Neutral9-3
KNSA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
